CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
Intrinsa Transdermal testosterone patchdrug
Likely dose
Intrinsa Transdermal testosterone patch 300 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01208038
NCT01208038Phase 4Completed
CompareCT.gov

Pilot Study: Evaluating the Effect of 300 Micrograms Testosterone Patches in Addition to Hormone Replacement Therapy on Arterial Compliance, Insulin Resistance and Sexual Desire.

Imperial College Healthcare NHS Trust·interventional·Posted Sep 23, 2010·Updated Jan 2, 2020

In Brief

A Phase 4 clinical trial evaluating Intrinsa Transdermal testosterone patch for Hypoactive Sexual Desire Disorder. Completed, enrolled 22 participants across 3 sites.

Detailed Summary

The purpose of this study is to examine the effect of the testosterone patch, in addition to hormone replacement therapy (HRT), on blood vessel walls, insulin levels and sexual desire.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoactive Sexual Desire Disorder
CountriesUnited Kingdom
CollaboratorsRoyal Brompton & Harefield NHS Foundation Trust, Chelsea and Westminster NHS Foundation Trust

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2010
Enrollment StartMar 1, 2011
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.8 years ago

Interventions

Intrinsa Transdermal testosterone patchdrug

300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks